S t u d y s e l e c t i o n
Original English-language studies were selected if they were randomized placebocontrolled trials of drug therapies other than hormone therapy in patients with UI confirmed by urodynamic assessment and outcomes included ≥ 1 of subjective improvement, results of a urodynamic evaluation, or adverse effects.
D a t a e x t r a c t i o n
3 independent investigators extracted data on number of patients, inclusion and exclusion criteria, type of drug, and outcomes. Quality of individual trials was assessed on the basis of the randomization process, patient exclusions after randomization, and patient compliance.
M a i n r e s u l t s 47 trials met the selection criteria, but 11 trials of terodiline were excluded from analysis because it was withdrawn from the market. Sample sizes in the remaining 36 trials ranged from 20 to 316. Meta-analysis was not done because of heterogeneity among trials. Only drugs that were assessed in > 1 trial are reported here. Results for the anticholinergic drugs oxybutinin, emepronium, and tolterodine are summarized in the Table. 12 trials assessed alternative drug regimens. Flavoxate had no effect on symptoms in 1 of 1 trial (n = 38) or adverse effects in 2 of 2 trials (n = 91). Flurbiprofen improved symptoms in 1 of 1 trial (n = 58), but increased adverse effects in 1 of 1 trial (n = 61) and had no effect on dry mouth in 2 of 2 trials (n = 121) or adverse effects that stopped treatment in 2 of 2 trials (n = 126).
C o n c l u s i o n
Limited evidence suggests that drugs commonly used for incontinence-oxybutinin, emepronium, tolterodine, and flavoxateare either ineffective or have a low rate of effectiveness that is counterbalanced by an increase in specific adverse effects. 
C o m m e n t a r y
Despite decades of using anticholinergic drugs for UI, few well-designed, controlled trials support the efficacy of these drugs. Haeusler and colleagues identified double-blind trials that were published up to October 2000. Only 8 of 36 studies enrolled > 100 patients, and outcomes were mostly based on subjective reports by patients rather than urodynamic results. Trials of nonpharmacologic therapies (1) that incorporated independent drug-placebo comparison arms that might have been included were not. 3 studies quoted by the U.S. Public Health Service Clinical Practice Guideline (2) as establishing the effectiveness of oxybutinin are not mentioned.
Only a small proportion of the trials with outcome data reported significant benefits. This may reflect small sample sizes, heterogeneous patient populations, and a relatively high placebo response rate (approximately 40% for reduction in incontinence episodes) (1). Better results have been obtained with biofeedback and behavioral therapy in geriatric outpatients (1) . These techniques are not currently available in routine clinical practice but perhaps should be part of our clinical training. None of the trials included elderly patients with dementia, a group with a high frequency of UI in whom delirium associated with anticholinergic agents is a major adverse effect.
An effective, safe, pharmacologic solution for incontinence continues to escape us, but clinicians can at least rely on easily implemented guidelines for diagnostic stratification (2, 3) and assist patients with treatment decisions, which may include a trial of medication. 
